Exploring hybrid mRNA vaccine technology for lasting immunity to COVID-19

Vaccine Insights 2024; 3(1), 13–16

DOI: 10.18609/vac.2024.004

Published: 2 February
Magnus Hoffmann

While COVID-19 vaccines have proven effective, the need for lasting immunity has prompted exploration beyond conventional approaches. Casey Nevins, Assistant Editor, Vaccine Insights, speaks with Magnus Hoffmann, Merkin Institute Fellow in the Merkin Institute for Translational Research at Caltech, about his work on developing a hybrid mRNA vaccine technology and its potential to address the limitations of current COVID-19 vaccines.